AI has rapidly moved from future ambition to operational reality across Life Sciences. From clinical data analysis and regulatory submissions to scientific engagement and market access, organisations are investing heavily in AI to improve productivity, accelerate workflows, and reduce costs.

But the challenge I increasingly see across the industry is not AI capability, but rather organisational readiness.

Many businesses are discovering that implementing AI is far easier than redesigning the operating model around it. While productivity gains are emerging within individual functions, isolated AI deployment alone is rarely delivering enterprise-wide transformation. Instead, AI is often accelerating one part of the organisation faster than governance, infrastructure, or decision-making processes can support.

I have seen organisations dramatically speed up scientific content generation and data analysis, only for compliance reviews, fragmented systems, or approval processes to become the next bottleneck. In many cases, AI simply exposes inefficiencies that already existed but were previously hidden by slower workflows.

This is particularly visible within Life Sciences, where regulatory complexity and compliance requirements create additional pressure points. Organisations may accelerate R&D or medical content development through AI, only for legal, regulatory, or patient engagement functions to struggle to keep pace.

At the same time, industry leaders are already making significant moves.

Novo Nordisk has partnered with OpenAI to accelerate AI adoption across drug discovery and development. Eli Lilly is collaborating with Nvidia to apply generative AI across pharmaceutical research, while Merck has partnered with Google Cloud to strengthen its AI and data capabilities. Novartis CEO Vas Narasimhan joining Anthropic’s board further signals how strategically important AI is becoming at the leadership level.

AstraZeneca is also embedding AI across its value chain, from its “Reinvent” R&D initiative through to AI-enabled clinical trial patient identification and continuous scoring models designed to improve recruitment and study execution.

What these organisations recognise is that long-term value will not come from standalone AI tools alone, but from building integrated operating models where data, governance, workflows, and decision-making function cohesively across the enterprise.

This is why successful AI transformation is ultimately not just a technology challenge, but an organisational design challenge.

Businesses need aligned leadership, interoperable systems, scalable governance, and operational structures capable of evolving at the same pace as the technology itself. They must also address growing questions around trust, accountability, compliance, transparency, and validation as AI becomes increasingly embedded within decision-making, patient engagement, and scientific communications.

Regulation is also evolving rapidly alongside adoption. In the UK, the MHRA continues to expand its regulatory approach to AI-enabled medical technologies, including ongoing work surrounding software and AI as medical devices, alongside initiatives such as the AI Airlock programme designed to support safe innovation. As AI becomes increasingly involved in areas such as diagnosis, treatment support, and patient interaction, organisations will need robust governance models capable of validating data provenance, monitoring outputs, and ensuring compliance across increasingly complex AI ecosystems.

Ultimately, as AI adoption accelerates, efficiency alone will no longer differentiate organisations. The businesses that create lasting value will be those that move beyond fragmented experimentation and build integrated AI ecosystems capable of supporting agility, compliance, scalability, and trust within an evolving regulatory environment.

The key question organisations must now ask themselves is whether their AI capabilities operate in isolated silos, or within an interconnected model where systems, data, governance, regulation, and decision-making work cohesively across the enterprise.